Vanda Pharmaceuticals (VNDA) FCF Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -5,426.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 9,545.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4,612.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -3,088.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 14,060.00 |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn | -3,304.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3,304.00 |
| Mar 31, 2026 | -14,833.00 |
| Dec 31, 2025 | -6,579.00 |
| Sep 30, 2025 | -7,593.00 |
| Jun 30, 2025 | -3,810.00 |
| Mar 31, 2025 | -7,371.00 |
| Dec 31, 2024 | -4,274.00 |
| Sep 30, 2024 | -4,436.00 |
| Jun 30, 2024 | -4,151.00 |
| Mar 31, 2024 | 147.00 |
| Dec 31, 2023 | -3,591.00 |
| Sep 30, 2023 | -2,048.00 |
| Jun 30, 2023 | -6,708.00 |
| Mar 31, 2023 | 5,301.00 |
| Dec 31, 2022 | -176.00 |
| Sep 30, 2022 | 984.00 |
| Jun 30, 2022 | -2,576.00 |
| Mar 31, 2022 | -1,279.00 |
| Dec 31, 2021 | 1,019.00 |
| Sep 30, 2021 | -400.00 |